EGFR and non-small cell lung carcinoma: The second clinical application of liquid biopsy in EGFR mutation-positive NSCLC is the evaluation of the most common acquired resistance mechanism to first and second-generation EGFR-TKIs (erlotinib, gefitinib and afatinib): T790M mutation [55, 56] (Fig. 3).